Back to home
Endothelial cell comparison
CB-ECFC vs iPSC-EC
How primary cord blood ECFCs (CB-ECFCs) compare to iPSC-derived endothelial cells — and why researchers choose primary cells when authentic endothelial function matters.
The short answer
iPSC-derived endothelial cells (iPSC-ECs) offer the appeal of homogeneity and the ability to engineer at the pluripotent stage. But despite a decade of protocol optimization, iPSC-ECs frequently underperform primary endothelial cells in functional assays — particularly in vivo vessel formation, sprouting angiogenesis, and barrier function — and they require weeks of differentiation per batch with significant lot-to-lot variability.
CB-ECFCs are primary endothelial cells with native vascular biology. Because they're clonally isolated from a single cord blood progenitor, they combine the homogeneity of iPSC-ECs with the authentic function of primary cells — and they're ready to use the moment you thaw the vial.
Side-by-side comparison
Attribute
CB-ECFC
ClonalStem
iPSC-EC
iPSC-derived
Cell origin
Primary cells — clonally isolated from cord blood
Differentiated from iPSCs via directed protocols
Endothelial identity
Bona fide primary endothelial cells with native function
Endothelial-like; transcriptome and function often incomplete
Population homogeneity
Homogeneous — clonal lineage
Homogeneous after sorting/selection
Differentiation variability
Not applicable — already primary endothelial cells
Significant batch-to-batch differentiation variability
Time to usable cells
Thaw and seed — ready in hours
2-4 weeks of differentiation per batch
In vivo vessel formation
Forms durable, perfused vessels in vivo
Often limited; many protocols yield immature endothelium
Sprouting angiogenesis
Robust sprouting in 3D matrices
Variable; some protocols underperform vs primary cells
Barrier function
Native primary endothelial barrier properties
Often immature; requires extensive optimization
Cost & complexity
Buy and use — no specialized differentiation expertise
Requires iPSC culture infrastructure and differentiation know-how
Genetic engineering
Compatible with standard transduction/transfection
Easier to engineer at iPSC stage before differentiation
Cell origin
CB-ECFC
Primary cells — clonally isolated from cord blood
iPSC-EC
Differentiated from iPSCs via directed protocols
Endothelial identity
CB-ECFC
Bona fide primary endothelial cells with native function
iPSC-EC
Endothelial-like; transcriptome and function often incomplete
Population homogeneity
CB-ECFC
Homogeneous — clonal lineage
iPSC-EC
Homogeneous after sorting/selection
Differentiation variability
CB-ECFC
Not applicable — already primary endothelial cells
iPSC-EC
Significant batch-to-batch differentiation variability
Time to usable cells
CB-ECFC
Thaw and seed — ready in hours
iPSC-EC
2-4 weeks of differentiation per batch
In vivo vessel formation
CB-ECFC
Forms durable, perfused vessels in vivo
iPSC-EC
Often limited; many protocols yield immature endothelium
Sprouting angiogenesis
CB-ECFC
Robust sprouting in 3D matrices
iPSC-EC
Variable; some protocols underperform vs primary cells
Barrier function
CB-ECFC
Native primary endothelial barrier properties
iPSC-EC
Often immature; requires extensive optimization
Cost & complexity
CB-ECFC
Buy and use — no specialized differentiation expertise
iPSC-EC
Requires iPSC culture infrastructure and differentiation know-how
Genetic engineering
CB-ECFC
Compatible with standard transduction/transfection
iPSC-EC
Easier to engineer at iPSC stage before differentiation
Try CB-ECFCs in your next experiment
Skip weeks of differentiation. Thaw, seed, and start your assay the same day — with primary endothelial biology and clonal reproducibility.
Frequently asked questions
- Are CB-ECFCs better than iPSC-derived endothelial cells?
- For functional vascular assays, primary CB-ECFCs generally outperform iPSC-ECs. iPSC-ECs are endothelial-like, and their transcriptome and function are often incomplete, particularly for in vivo vessel formation, sprouting angiogenesis, and barrier function. CB-ECFCs are bona fide primary endothelial cells that are still homogeneous thanks to their clonal origin.
- How long does it take to get usable cells?
- CB-ECFCs are thawed and seeded, so they are ready in hours. iPSC-EC workflows require two to four weeks of directed differentiation per batch, plus iPSC culture infrastructure and differentiation expertise.
- Is batch-to-batch variability lower with CB-ECFCs?
- Yes. iPSC-EC differentiation introduces significant batch-to-batch variability in yield and phenotype. CB-ECFCs come from a single clonal lineage, so vials are consistent across experiments and over time.
- Do iPSC-ECs form perfused vessels in vivo?
- Often only poorly. Many differentiation protocols yield immature endothelium with limited vessel-forming capacity. CB-ECFCs form durable, perfused vessels in vivo, which makes them the stronger choice for vasculogenesis models.
- When do iPSC-ECs still make sense?
- When patient-specific genetics or extensive genetic engineering matter, since editing is easier at the iPSC stage before differentiation. For phenotype stability, cost, speed, and native endothelial function, CB-ECFCs are the more practical option.